These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17442687)

  • 1. The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin.
    Schwartz JI; Agrawal NG; Hartford AH; Cote J; Hunt TL; Verbesselt R; Eckols DR; Gottesdiener KM
    J Clin Pharmacol; 2007 May; 47(5):620-7. PubMed ID: 17442687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
    Schwartz JI; Bugianesi KJ; Ebel DL; De Smet M; Haesen R; Larson PJ; Ko A; Verbesselt R; Hunt TL; Lins R; Lens S; Porras AG; Dieck J; Keymeulen B; Gertz BJ
    Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium.
    Modi NB; Kell S; Simon M; Vargas R
    J Clin Pharmacol; 2005 Aug; 45(8):919-26. PubMed ID: 16027402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
    Depré M; Van Hecken A; Oeyen M; De Lepeleire I; Laethem T; Rothenberg P; Petty KJ; Majumdar A; Crumley T; Panebianco D; Bergman A; de Hoon JN
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):341-6. PubMed ID: 15983826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ
    Br J Clin Pharmacol; 2004 May; 57(5):592-9. PubMed ID: 15089812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Van Hecken A; Depré M; Verbesselt R; Wynants K; De Lepeleire I; Arnout J; Wong PH; Freeman A; Holland S; Gertz B; De Schepper PJ
    J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
    Stockis A; van Lier JJ; Cawello W; Kumke T; Eckhardt K
    Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.
    Ragueneau-Majlessi I; Levy RH; Meyerhoff C
    Epilepsy Res; 2001 Nov; 47(1-2):55-63. PubMed ID: 11673021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
    Simonson SG; Martin PD; Mitchell PD; Lasseter K; Gibson G; Schneck DW
    J Clin Pharmacol; 2005 Aug; 45(8):927-34. PubMed ID: 16027403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
    Yin OQ; Gallagher N; Fischer D; Zhao L; Zhou W; Leroy E; Golor G; Schran H
    Clin Drug Investig; 2011; 31(3):169-79. PubMed ID: 21184622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.
    Dieterle W; Corynen S; Mann J
    Br J Clin Pharmacol; 2004 Oct; 58(4):433-6. PubMed ID: 15373937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
    Kosoglou T; Zhu Y; Xuan F; Black L; Johnson-Levonas AO; Martinho M; Statkevich P; Cutler DL
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1509-16. PubMed ID: 22476387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
    Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
    Schall R; Müller FO; Hundt HK; Duursema L; Groenewoud G; Middle MV
    Arzneimittelforschung; 1996 Jan; 46(1):41-6. PubMed ID: 8821516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
    Padhi D; Sullivan JT
    Drugs R D; 2007; 8(2):79-87. PubMed ID: 17324005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ
    Br J Clin Pharmacol; 2005 Apr; 59(4):425-32. PubMed ID: 15801937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.
    Weiss D; Knight R; Zhou S; Palmisano M; Chen N
    Clin Drug Investig; 2015 Jul; 35(7):455-61. PubMed ID: 26024727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.